D08 W2A8.

Office of the Assistant National Director, www.hse.ie Primary Care Access and Integration @hselive

Rm 243, Dr Steevens Hospital, Steevens Lane, Dublin 8. D08 W2A8. **T:** 01 6352209/2682 **E:** Primarycare.Al@hse.ie

29th November 2024

Deputy Phelan, Dáil Éireann, Leinster House, Kildare Street, Dublin 2.

PQ 41426/24 To ask the Minister for Health the number of type 1 diabetes patients that were approved to use reimbursed diabetes technology; if he will provide a breakdown on the suppliers; the total costs provided to each supplier for this technology, between the years 2020 to 2024; and if he will make a statement on the matter. (Continuous Glucose Monitors)

-John Paul Phelan

Dear Deputy Phelan,

The Health Service Executive (HSE) has been requested to reply directly to you in the context of the above Parliamentary Question (PQ 41426/24) which you submitted to the Minister for Health for response.

Please see outlined in the tables below the number of patients approved and receiving Continuous Glucose Monitors (CGM) and the total spend on CGM technology per annum by the HSE from 2020 to 2024 YTD, which is the latest data available.

Table 1. Number of patients approved and receiving Continuous Glucose Monitors (CGM)

Year	2020	2021	2022	2023	2024 Q1 & Q2
Number of patients approved and receiving CGM per annum	9,374	12,202	18,482	28,583	25,946

Table 2. Total Spend on CGM technology per annum by the HSE

Total Spend on CGM technology per annum by the HSE	2020	2021	2022	2023	2024 Q1 & Q2
Abbott	€3,871,590.37	€4,368,235.55	€4,536,483.78	€3,608,023.64	€2,661,162.77
Dexcom	€7,671,444.25	€17,033,989.30	€28,040,424.67	€44,545,673.67	€28,989,514.44
Medtronic	€5,823,783.26	€6,868,540.86	€9,388,785.25	€13,142,562.38	€3,105,875.35
Windzor					
Pharma	€0.00	€47.78	€5,867.37	€92.48	€412.78
Total Spend	€17,366,817.88	€28,270,813.49	€41,971,561.07	€61,296,352.17	€34,756,965.34



I trust this is of assistance.

Sain Me tot

Sean McArt

General Manager

Primary Care Access & Integration